VALENTIN ISACESCU: Open Payments
NPI 1972602720 · OCEANSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,075 in 157 payments from 15 companies in 2025. Trend: 2023 $3,442 · 2024 $3,090 · 2025 $4,075
Food & beverage: $4,075
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 43 | $708 |
| Neurocrine BioSciences, Inc. | 22 | $592 |
| Alkermes, Inc. | 20 | $534 |
| Janssen Pharmaceuticals, Inc | 15 | $368 |
| Otsuka America Pharmaceutical, Inc. | 11 | $346 |
| Teva Pharmaceuticals USA, Inc. | 10 | $314 |
| Lundbeck LLC | 14 | $312 |
| Neuronetics, Inc. | 3 | $294 |
| E.R. Squibb & Sons, L.L.C. | 5 | $212 |
| ABBVIE INC. | 5 | $110 |
Products named: CAPLYTA, REXULTI, INGREZZA, ARISTADA, NEUROSTAR TMS THERAPY SYSTEM, INVEGA SUSTENNA, COBENFY, UZEDY.
Industry payments across CA — which companies pay providers there.
